Article Text

Download PDFPDF
Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Study concept and design: CW, OA and MPW. Acquisition and analysis of data: all. Drafting of manuscript: CW, MTW. Critical revision of the manuscript for important intellectual content: all.

  • Competing interests CW: consulting and/or research funding: Bayer, Biogen, Novartis, TEVA. HPH: received honoraria for consulting and speaking at symposia from Bayer, Biogen, Genzyme, Merck Serono, Novartis Pharma, Roche and Teva Sanofi-Aventis. JK: accepted speaker and consulting fees from Merck Serono, Biogen, TEVA, Genzyme, Roche and Novartis. OA: accepted speakers honoraria and research funding from Biogen. MPW: accepted speaker and consulting fees from Biogen, Novartis, Roche and Genzyme.

  • Patient consent All patients signed a written informed consent stating that data and imaging can be used for research and education, approved by the local institutional review board at VUmc.

  • Provenance and peer review Not commissioned; externally peer reviewed.